ArticleAmerican journal of translational research2023
Efficacy of bumetanide tablets combined with valsartan in the treatment of elderly patients with chronic glomerulonephritis and its effects on renal function and hemodynamics.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study was designed to determine the efficacy of bumetanide tablets combined with valsartan for the treatment of elderly patients with chronic glomerulonephritis (CGN) and its effects on renal function and hemodynamics.
methodsData from 122 elderly patients with CGN admitted to Pingdingshan First People's Hospital from April 2019 to January 2020 were analyzed retrospectively. Among them, 65 patients treated with bumetanide tablets combined with valsartan were assigned to a study group and the other 57 patients treated with bumetanide tablets alone were assigned to a control group. The clinical efficacy, renal function, hemodynamics and inflammatory factors of the two groups were compared, and the incidence of adverse reactions during treatment was calculated. The risk factors of unfavorable prognosis were analyzed by multiple logistics regression.
resultsThe study group showed a significantly higher total response rate than the control group (P<0.05), and no notable difference was found in the incidence of adverse reactions between the two groups (P>0.05). Before treatment, the examination results of renal function and hemodynamics of the two groups were not significantly different (P>0.05), and the results of both groups were improved after treatment (P<0.05). Furthermore, the study group showed significantly higher levels of renal function and hemodynamics and lower levels of inflammatory factors than the control group after treatment (P<0.05). Older age (OR: 1.883, 95% CI: 1.226-2.892), higher post-treatment blood urea nitrogen (OR: 4.328, 95% CI: 1.117-16.778) and lower post-treatment end-diastolic flow velocity (OR: 0.419, 95% CI: 0.117-0.992) were independent risk factors for unfavorable prognosis of patients.
conclusionBumetanide tablets combined with valsartan are remarkably effective for elderly patients with CGN. This combined method can substantially improve the renal function and hemodynamics of the patients, so it has a high clinical application value in the future.
Indexed as
Identifiers
37303676PMC10250995W4380291047What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.